The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The implementing agency of PMBJP has invited online applications for opening of new Jan Aushadhi Kendras in 651 districts of different States/UTs
Subscribe To Our Newsletter & Stay Updated
